• About us
• Contact

Advertisement

Organisation › Details

Dicerna Pharmaceuticals Inc. (Nasdaq: DRNA)

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. The Company is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. *

 

	Start	2007-11-01 established
	Industry	RNAi drug (RNAi therapeutic)
	Industry 2	GalXC™ RNAi technology platform
	Person	Fambrough, Douglas M. (Dicerna Pharmaceuticals 201711 CEO)
	Region	Cambridge, MA
	Country	United States (USA)
	Street	87 Cambridgepark Drive
	City	02140 Cambridge, MA
	Tel	+1-617-621-8097
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Boehringer Ingelheim. (11/2/17). "Press Release: Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)". Ingelheim & Cambridge, MA.
		Record changed: 2023-07-10

Advertisement

More documents for Dicerna Pharmaceuticals Inc. (Nasdaq: DRNA)

• [1] Dicerna Pharmaceuticals, Inc.. (11/18/21). "Press Release: Novo Nordisk to Acquire Dicerna". Lexington, MA....
• [2] Novo Nordisk A/S. (11/18/19). "Press Release: Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-related Cardio-metabolic Diseases". Lexington, MA & Bagsværd....
• [3] Boehringer Ingelheim. (1/4/19). "Press Release: Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna". Ingelheim & Cambridge, MA....
• [4] Alexion Pharmaceuticals, Inc.. (10/24/18). "Press Release: Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases". Boston, MA & Cambridge, MA....
• [5] Dicerna Pharmaceuticals, Inc.. (11/8/17). "Press Release: Dicerna to Present at the Stifel 2017 Healthcare Conference". Cambridge, MA....
• [6] Boehringer Ingelheim. (11/2/17). "Press Release: Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)". Ingelheim & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.